Pioglitazone

Generic Name
Pioglitazone
Brand Names
Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
Drug Type
Small Molecule
Chemical Formula
C19H20N2O3S
CAS Number
111025-46-8
Unique Ingredient Identifier
X4OV71U42S
Background

Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medications, which also includes rosiglitazone and troglitazone, exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.

Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.

Indication

Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.

Associated Conditions
Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
Associated Therapies
-

Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-09-13
Last Posted Date
2016-04-12
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
24
Registration Number
NCT01432405
Locations
🇺🇸

Baylor College of Medicine, Houston, Texas, United States

Pioglitazone and Metformin in Diabetic Children

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-07-19
Last Posted Date
2011-07-19
Lead Sponsor
Coordinación de Investigación en Salud, Mexico
Target Recruit Count
56
Registration Number
NCT01396564
Locations
🇲🇽

Endocrine Outpatient Clinic of the Hospital de Pediatria del CMN "Siglo XXI", Mexico City, DF, Mexico

Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-07-18
Last Posted Date
2016-02-23
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
32
Registration Number
NCT01395784
Locations
🇺🇸

Columbia Univ/ NYSPI Division on Substance Abuse, New York, New York, United States

Glucose Control in Pre-Diabetic Renal Transplant Patients

First Posted Date
2011-05-02
Last Posted Date
2011-12-05
Lead Sponsor
Marcus Saemann
Target Recruit Count
51
Registration Number
NCT01346254
Locations
🇦🇹

Allgemeines Krankenhaus der Stadt Wien, Universitätskliniken, Wien, Austria

Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes

First Posted Date
2011-04-20
Last Posted Date
2011-05-09
Lead Sponsor
Korea University Anam Hospital
Target Recruit Count
80
Registration Number
NCT01339143
Locations
🇰🇷

Korea University Anam Hospital, Seoul, Korea, Republic of

The Effect of Pioglitazone on Neointima Volume and Characteristics Observed by Optical Coherence Tomography (OCT)

First Posted Date
2011-04-08
Last Posted Date
2014-03-04
Lead Sponsor
Korea University Anam Hospital
Target Recruit Count
94
Registration Number
NCT01331967
Locations
🇰🇷

Korea University Anam Hospital, Seoul, Korea, Republic of

Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus

First Posted Date
2011-03-24
Last Posted Date
2014-10-01
Lead Sponsor
National Heart Institute, Mexico
Target Recruit Count
30
Registration Number
NCT01322308

Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan

First Posted Date
2011-03-18
Last Posted Date
2012-02-03
Lead Sponsor
Takeda
Target Recruit Count
339
Registration Number
NCT01318070

Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects

First Posted Date
2011-03-07
Last Posted Date
2011-07-07
Lead Sponsor
AstraZeneca
Target Recruit Count
15
Registration Number
NCT01309854
Locations
🇺🇸

Research Site, Overland Park, Kansas, United States

Effect of Adipokines in Hemodialysis Patients

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2011-02-23
Last Posted Date
2016-10-03
Lead Sponsor
University of Utah
Target Recruit Count
95
Registration Number
NCT01301027
Locations
🇺🇸

University of Utah, Salt Lake City, Utah, United States

🇺🇸

University of Colorado, Denver, Colorado, United States

© Copyright 2024. All Rights Reserved by MedPath